<?xml version='1.0' encoding='utf-8'?>
<document id="23980564"><sentence text="Acute kidney injury caused by tenofovir disoproxil fumarate and diclofenac co-administration."><entity charOffset="30-59" id="DDI-PubMed.23980564.s1.e0" text="tenofovir disoproxil fumarate" /><entity charOffset="64-74" id="DDI-PubMed.23980564.s1.e1" text="diclofenac" /><pair ddi="false" e1="DDI-PubMed.23980564.s1.e0" e2="DDI-PubMed.23980564.s1.e0" /><pair ddi="false" e1="DDI-PubMed.23980564.s1.e0" e2="DDI-PubMed.23980564.s1.e1" /></sentence><sentence text="The renal elimination of tenofovir (TFV) may be subject to renal drug-drug interactions that may increase the risk of kidney injury"><entity charOffset="25-34" id="DDI-PubMed.23980564.s2.e0" text="tenofovir" /><entity charOffset="36-39" id="DDI-PubMed.23980564.s2.e1" text="TFV" /><pair ddi="false" e1="DDI-PubMed.23980564.s2.e0" e2="DDI-PubMed.23980564.s2.e0" /><pair ddi="false" e1="DDI-PubMed.23980564.s2.e0" e2="DDI-PubMed.23980564.s2.e1" /></sentence><sentence text=" Case reports indicated that diclofenac might increase TFV-associated nephrotoxicity via a drug-drug interaction, leading to an increased intracellular TFV concentration in proximal tubular cells"><entity charOffset="29-39" id="DDI-PubMed.23980564.s3.e0" text="diclofenac" /><entity charOffset="55-64" id="DDI-PubMed.23980564.s3.e1" text="TFV" /><entity charOffset="152-161" id="DDI-PubMed.23980564.s3.e2" text="TFV" /><pair ddi="false" e1="DDI-PubMed.23980564.s3.e0" e2="DDI-PubMed.23980564.s3.e0" /><pair ddi="false" e1="DDI-PubMed.23980564.s3.e0" e2="DDI-PubMed.23980564.s3.e1" /><pair ddi="false" e1="DDI-PubMed.23980564.s3.e0" e2="DDI-PubMed.23980564.s3.e2" /><pair ddi="false" e1="DDI-PubMed.23980564.s3.e1" e2="DDI-PubMed.23980564.s3.e1" /><pair ddi="false" e1="DDI-PubMed.23980564.s3.e1" e2="DDI-PubMed.23980564.s3.e2" /></sentence><sentence text="" /><sentence text="A retrospective analysis of data for all patients from the Frankfurt HIV Cohort (FHC) who had diclofenac prescriptions between January 2008 and June 2012 was carried out"><entity charOffset="94-104" id="DDI-PubMed.23980564.s5.e0" text="diclofenac" /></sentence><sentence text="" /><sentence text="Among 89 patients with diclofenac use, 61 patients (68"><entity charOffset="23-33" id="DDI-PubMed.23980564.s7.e0" text="diclofenac" /></sentence><sentence text="5%) were treated with tenofovir disoproxil fumarate (TDF) and 28 patients (31"><entity charOffset="22-51" id="DDI-PubMed.23980564.s8.e0" text="tenofovir disoproxil fumarate" /><entity charOffset="53-56" id="DDI-PubMed.23980564.s8.e1" text="TDF" /><pair ddi="false" e1="DDI-PubMed.23980564.s8.e0" e2="DDI-PubMed.23980564.s8.e0" /><pair ddi="false" e1="DDI-PubMed.23980564.s8.e0" e2="DDI-PubMed.23980564.s8.e1" /></sentence><sentence text="5%) were treated with TDF-sparing combination antiretroviral therapy (cART)"><entity charOffset="22-24" id="DDI-PubMed.23980564.s9.e0" text="TDF" /></sentence><sentence text=" Thirteen patients (14" /><sentence text="6%) developed acute kidney injury (AKI) shortly after initiating diclofenac treatment"><entity charOffset="65-75" id="DDI-PubMed.23980564.s11.e0" text="diclofenac" /></sentence><sentence text=" AKI occurred exclusively in TDF-treated patients, although all had previously stable renal function"><entity charOffset="29-38" id="DDI-PubMed.23980564.s12.e0" text="TDF" /></sentence><sentence text=" All cases were accompanied by new onset of at least two parameters indicating proximal tubular damage, such as normoglycaemic-glucosuria and hypophosphataemia" /><sentence text=" TFV-associated nephrotoxicity was demonstrated by renal biopsy in four cases"><entity charOffset="1-3" id="DDI-PubMed.23980564.s14.e0" text="TFV" /></sentence><sentence text=" Additionally, 11" /><sentence text="5% of patients on TDF treatment developed new-onset proximal tubular damage, while having a preserved glomerular filtration rate"><entity charOffset="18-20" id="DDI-PubMed.23980564.s16.e0" text="TDF" /></sentence><sentence text=" In contrast, diclofenac did not affect renal function in patients with TDF-sparing cART, as only one case of isolated hypophataemia was observed in these patients"><entity charOffset="14-24" id="DDI-PubMed.23980564.s17.e0" text="diclofenac" /><entity charOffset="72-81" id="DDI-PubMed.23980564.s17.e1" text="TDF" /><pair ddi="false" e1="DDI-PubMed.23980564.s17.e0" e2="DDI-PubMed.23980564.s17.e0" /><pair ddi="false" e1="DDI-PubMed.23980564.s17.e0" e2="DDI-PubMed.23980564.s17.e1" /></sentence><sentence text=" In univariate analysis, risk factors for AKI were TDF-containing cART (P = 0"><entity charOffset="51-53" id="DDI-PubMed.23980564.s18.e0" text="TDF" /></sentence><sentence text="0076) and pre-existing hypophosphataemia (P = 0" /><sentence text="0086)" /><sentence text="" /><sentence text="Drug-drug interaction caused by diclofenac could exacerbate TFV-associated nephrotoxicity"><entity charOffset="32-42" id="DDI-PubMed.23980564.s22.e0" text="diclofenac" /><entity charOffset="60-69" id="DDI-PubMed.23980564.s22.e1" text="TFV" /><pair ddi="false" e1="DDI-PubMed.23980564.s22.e0" e2="DDI-PubMed.23980564.s22.e0" /><pair ddi="false" e1="DDI-PubMed.23980564.s22.e0" e2="DDI-PubMed.23980564.s22.e1" /></sentence><sentence text=" Diclofenac should be used with caution in patients on TDF therapy, especially in those with hypophosphataemia"><entity charOffset="1-11" id="DDI-PubMed.23980564.s23.e0" text="Diclofenac" /><entity charOffset="55-64" id="DDI-PubMed.23980564.s23.e1" text="TDF" /><pair ddi="false" e1="DDI-PubMed.23980564.s23.e0" e2="DDI-PubMed.23980564.s23.e0" /><pair ddi="false" e1="DDI-PubMed.23980564.s23.e0" e2="DDI-PubMed.23980564.s23.e1" /></sentence><sentence text=" Our findings need to be confirmed in larger studies" /><sentence text="" /></document>